B-cell maturation antigen (BCMA)-targeted therapy has become an important treatment consideration for relapsed refractory (R/R) multiple myeloma (MM) patients (Yu et al., 2020). This novel treatment is rapidly emerging due to BCMA's highly selective expression in malignant plasma cells. Several BCMA-targeted agents are currently in active clinical development. Patient education, risk mitigation, BCMA-related toxicity management, and long-term follow-up are important considerations for advanced practitioners when managing patients with R/R MM undergoing this novel treatment.
展开▼
